Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,202,176 | 1,863,972 | 1,803,694 | 1,550,710 | 1,625,500 |
| Marketable Securities | 85,194 | 78,804 | 58,556 | 144,775 | 82,044 |
| Receivables | 1,895,913 | 1,945,189 | 1,751,388 | 1,766,091 | 1,702,818 |
| Inventories | 1,935,147 | 1,799,618 | 1,744,982 | 1,617,369 | 1,603,401 |
| Income taxes - deferred | 224,429 | 211,938 | 262,641 | 222,572 | 213,448 |
| Other current assets | 176,355 | 217,748 | 84,302 | 144,175 | 226,903 |
| TOTAL | $7,072,529 | $6,663,097 | $6,156,347 | $5,880,379 | $5,844,102 |
| Non-Current Assets | |||||
| PPE Net | 1,135,993 | 1,125,794 | 1,100,259 | 856,184 | 811,799 |
| Investments And Advances | 688,428 | 688,254 | 719,836 | 955,603 | 564,130 |
| Intangibles | 13,244,157 | 13,265,707 | 12,797,309 | 12,814,269 | 12,830,109 |
| Other Non-Current Assets | 483,262 | 468,815 | 466,086 | 457,394 | 451,812 |
| TOTAL | $15,551,840 | $15,548,570 | $15,083,490 | $15,083,450 | $14,657,850 |
| Total Assets | $22,624,370 | $22,211,670 | $21,239,840 | $20,963,830 | $20,501,950 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,488,225 | 942,811 | 1,169,490 | 1,730,895 | 1,972,816 |
| Accounts payable and accrued liabilities | 1,390,641 | 1,356,372 | 1,327,339 | 1,319,670 | 1,367,353 |
| Accrued Expenses | 1,076,780 | 1,028,414 | 949,741 | 987,844 | 916,661 |
| TOTAL | $4,937,138 | $4,290,215 | $4,237,897 | $4,802,148 | $4,986,674 |
| Non-Current Liabilities | |||||
| Long Term Debt | 6,074,179 | 7,268,123 | 7,304,528 | 7,262,028 | 7,281,572 |
| Deferred Revenues | 112,119 | 124,369 | 103,162 | 99,048 | 93,660 |
| Other Non-Current Liabilities | 127,577 | 114,726 | 126,584 | 133,125 | 132,145 |
| TOTAL | $6,343,852 | $7,528,980 | $7,458,219 | $7,411,519 | $7,431,889 |
| Total Liabilities | $11,280,990 | $11,819,200 | $11,696,120 | $12,213,670 | $12,418,560 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,530,626 | 1,525,356 | 1,522,393 | 1,515,296 | 1,513,137 |
| Common Shares | 765 | 760 | 1,519 | 758 | 756 |
| Retained earnings | 5,065,839 | 4,301,539 | 3,704,744 | 3,139,393 | 2,663,077 |
| Other shareholders' equity | 281,751 | 261,045 | 195,515 | 174,769 | 205,644 |
| TOTAL | $11,343,380 | $10,392,470 | $9,543,722 | $8,750,162 | $8,083,387 |
| Total Liabilities And Equity | $22,624,370 | $22,211,670 | $21,239,842 | $20,963,832 | $20,501,947 |